Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis.
Borja de la Sen-CorcueraJesús MonteroRonald M Sánchez-ÁvilaGorka OriveEduardo AntiuaManuel Caro-MagdalenoJesús Merayo-LlovesPublished in: Clinical ophthalmology (Auckland, N.Z.) (2020)
Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties.